BioSpace News Archive

Roche announced the research use only launch of three new automated digital pathology algorithms, uPath Ki-67, uPath ER and uPath PR image analysis for breast cancer, which are important biomarkers for breast cancer patients.

Olympus Corporation, has clarified the direction of its medical business with the aim of achieving further growth and profitability by elevating the standard of care in targeted disease states.

Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced it has entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis’ investigational antisense medicine for the treatment of transthyretin amyloidosis.

Aerie Pharmaceuticals, Inc. announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® 0.02% and Rocklatan®/Roclanda® 0.02%/0.005%.

Hansa Biopharma AB and Medison Pharma announce a multiregional agreement for Medison to commercialize Hansa’s desensitization treatment for kidney transplants in Central Eastern Europe and Israel.

Alvotech Holdings S.A., a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II, a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P., announced that they have entered into a definitive merger agreement.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today an additional $150 million commitment through Merck for Mothers to further advance the initiative’s mission of helping create a world where no woman has to die giving life.

HEXO Corp (“HEXO”, or the “Company”) (TSX: HEXO; NASDAQ: HEXO) plans to release its financial results for the fiscal quarter ended October 31, 2021, before market hours on December 14, 2021, as well as host a webcast for investors beginning at 8:30 a.m. EST.

Caris Life Sciences® (Caris), announced today that it will present results at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional vaccine efficacy and safety data from its Phase 2b CYPRESS study of its respiratory syncytial virus (RSV) adult vaccine candidate.